ELOCTATE®—the only FVIII powered by Fc Fusion

Experience Fc Fusion technology in action

Fc Fusion MOE

ELOCTATE contains the Fc region of IgG11

IgG1 allows ELOCTATE to extend its half-life by binding to the neonatal Fc receptor1

IgG1 is a naturally occurring protein that has anti-inflammatory and immunomodulatory properties1-3

The molecular mechanism behind the effects achieved by ELOCTATE is not
yet fully understood, including the interaction with cellular Fc receptors that
ELOCTATE may interact with3

Poly vector 4,-d-,1-01 ELOCTATE Fc Fusion MOE

Fc Fusion helps ELOCTATE stay in circulation through a natural pathway and does not accumulate1,4

Fc=fragment crystallizable; FVIII=factor VIII; IgG1=immunoglobulin G; MOE=mechanism of extension.

Sanofi Logo

This site is intended for United States Residents only.

© 2022 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi are registered trademarks of Sanofi or an affiliate. MyELOCTATE is owned by Genzyme Corporation.
All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi.

MAT-US-2003082-v5.0-03/2022 Last Updated: March 2022